Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation

 

Contact: Mototaka Senda, Ph.D.
Phone: (1)510-468-3372
E-mail: ousvo@okayama-u.ac.jp

Patent number: US9696321B2

Description

The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.

 

Category:
Life Science
Keyword:
HRG, SIRS, Neutrophil activation

Back to List